

Antithrombotic Therapy for VTE Disease

Chest

160, e545-e608

DOI: [10.1016/j.chest.2021.07.055](https://doi.org/10.1016/j.chest.2021.07.055)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Venous thromboembolism: Recent advancement and future perspective. Journal of Cardiology, 2022, 79, 79-89.	0.8	19
2	Initial experience and early outcomes of the management of acute pulmonary embolism using the FlowTrier mechanical thrombectomy device. Journal of Cardiovascular Surgery, 2021, , .	0.3	1
3	The role of the PERT team in 2021. Thrombosis Update, 2022, 6, 100092.	0.4	6
4	Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. Frontiers in Cardiovascular Medicine, 2021, 8, 787235.	1.1	4
5	Clinical Management of Thrombotic Antiphospholipid Syndrome. Journal of Clinical Medicine, 2022, 11, 735.	1.0	11
6	Management and Outcomes of Adults Diagnosed with Acute Pulmonary Embolism in Primary Care: Community-Based Retrospective Cohort Study. Journal of General Internal Medicine, 2022, , 1.	1.3	8
7	Anticoagulants in the treatment of superficial vein thrombosis of lower limbs: possibilities and limitations. Atherothrombosis, 2022, 11, 94-102.	0.1	0
8	Prevalence, Characteristics, and Outcomes of Emergency Department Discharge Among Patients With Sepsis. JAMA Network Open, 2022, 5, e2147882.	2.8	10
9	Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction. Cardiology and Therapy, 2022, 11, 49-79.	1.1	2
10	Pharmacological and interventional management of pulmonary embolism: where do we stand?. Future Cardiology, 2022, 18, 191-206.	0.5	3
11	Inherited Thrombophilia in the Era of Direct Oral Anticoagulants. International Journal of Molecular Sciences, 2022, 23, 1821.	1.8	14
12	Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism. Trends in Cardiovascular Medicine, 2023, 33, 336-343.	2.3	6
13	Subsegmental Pulmonary Embolism: To Treat or Not to Treat?. , 2022, 19, .		0
14	Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210829.	0.7	7
15	Antithrombotic Therapy After Venous Interventions: <i>AJR</i> Expert Panel Narrative Review. American Journal of Roentgenology, 2022, 219, 175-187.	1.0	8
16	Asymptomatic pulmonary thromboembolism diagnosed based on prolonged fever after gastric cancer surgery: A case report with literature review. International Journal of Surgery Case Reports, 2022, 92, 106836.	0.2	0
17	The utility of hereditary thrombophilia testing among patients with lower extremity deep vein thrombosis.. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, , .	0.9	0
18	Rebuttal From Dr David Jimenez etÂal. Chest, 2022, 161, 1453-1455.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Rebuttal From Dr Tritschler etÂal. Chest, 2022, , .	0.4	0
20	Complications of Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America, 2022, 36, 353-363.	0.9	2
21	Pulmonary embolism management in the emergency department: part 2. Emergency Medicine Journal, 2023, 40, 69-75.	0.4	4
22	Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism. Blood Advances, 2023, 7, 205-213.	2.5	2
24	Thrombotic burden, D-dimer levels and complete compression ultrasound for diagnosis of acute symptomatic deep vein thrombosis of the lower limbs. Thrombosis Research, 2022, 213, 163-169.	0.8	1
25	Effectiveness and safety of extended oral anticoagulant therapy in patients with venous thromboembolism: a retrospective cohort study. Clinical Pharmacology and Therapeutics, 2022, , .	2.3	5
26	Anticoagulant Prescriptions Provided in US Ambulatory Practice, 2014 to 2016. Journal of General Internal Medicine, 2022, , 1.	1.3	0
27	Interventional Therapies for Acute Pulmonary Embolism. Surgical Clinics of North America, 2022, 102, 429-447.	0.5	5
28	Is catheter-based foam sclerotherapy more effective than direct foam sclerotherapy when combined with high ligation for the treatment of primary great saphenous vein incompetence?. Vascular, 2022, , 170853812210948.	0.4	0
32	Subsegmental pulmonary embolism and anticoagulant therapy: the impact of clinical context. Internal Medicine Journal, 2023, 53, 1435-1443.	0.5	2
33	Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives. Vascular Health and Risk Management, 0, Volume 18, 359-373.	1.0	25
34	Cancer-Associated Deep Vein Thrombosis: Insights from Randomized Trials and Real-Life Practice. Flebologiya, 2022, 16, 156.	0.2	1
35	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. American Heart Journal, 2022, 251, 43-53.	1.2	59
36	Sustainability of a Clinical Decision Support Intervention for Outpatient Care for Emergency Department Patients With Acute Pulmonary Embolism. JAMA Network Open, 2022, 5, e2212340.	2.8	10
37	Antithrombotic Therapy for Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 2141.	3.8	3
38	Anesthetic management for intraoperative acute pulmonary embolism during inferior vena cava tumor thrombus surgery: A case report. World Journal of Clinical Cases, 2022, 10, 5111-5118.	0.3	0
39	SCAI Guidelines for the Management of Patent Foramen Ovale. , 2022, 1, 100039.		28
40	Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. Journal of Thrombosis and Haemostasis, 2022, 20, 1910-1919.	1.9	12

#	ARTICLE	IF	CITATIONS
41	Physician perceptions and use of reduced-dose direct oral anticoagulants for extended phase venous thromboembolism treatment. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12740.	1.0	1
42	Concomitant post-traumatic ocular and cerebral fat embolism syndrome and thrombotic pulmonary embolism. <i>Medicine (United States)</i> , 2022, 101, e29331.	0.4	0
43	Extended Anticoagulation After Pulmonary Embolism: A Multicenter Observational Cohort Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	5
44	Cerebrovascular Complications of COVID-19 Disease in Children: A Single-Center Case Series. <i>Pediatric Neurology</i> , 2022, 134, 18-24.	1.0	4
45	Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH AC Registry): A Nationwide Prospective Cohort Study in Japan. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
46	Direct Oral Anticoagulants for Anticoagulation after Initial Management of Venous Thromboembolism. <i>Annals of Phlebology</i> , 2022, 20, 9-14.	0.4	0
47	The Ottawa Score Performs Poorly to Identify Cancer Patients at High Risk of Recurrent Venous Thromboembolism: Insights from the TROPIQUE Study and Updated Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3729.	1.0	1
48	Type of Oral Anticoagulant and Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for VTE—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 79.	3.8	0
49	D-dimer: old dogmas, new (COVID-19) tricks. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 841-850.	1.4	17
50	Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2226-2236.	1.9	23
51	Type of Oral Anticoagulant and Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for VTE. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 78.	3.8	0
52	Prognostic role of serial electrocardiographic changes in patients with acute pulmonary embolism. Data from the Italian Pulmonary Embolism Registry. <i>Thrombosis Research</i> , 2022, 217, 15-21.	0.8	7
53	Antiplatelet agents for the treatment of deep venous thrombosis. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	9
54	A review of inferior vena cava filters. <i>British Journal of Radiology</i> , 2023, 96, .	1.0	8
55	Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and meta-analysis. <i>British Journal of Haematology</i> , 2022, 199, 130-142.	1.2	5
56	From 3 to 6 months to forever—oral contraceptives, venous thrombosis and duration of anticoagulation. A challenging decision. <i>British Journal of Haematology</i> , 0, , .	1.2	0
57	Risk stratification and treatment of pulmonary embolism with intermediate-risk of mortality. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 375-383.	1.2	2
59	Catheter-related thrombosis (CRT) in patients with solid tumors: a narrative review and clinical guidance for daily care. <i>Supportive Care in Cancer</i> , 2022, 30, 8577-8588.	1.0	6

#	ARTICLE	IF	CITATIONS
60	Evaluating cardiopulmonary function following acute pulmonary embolism. Expert Review of Cardiovascular Therapy, 2022, 20, 747-760.	0.6	1
61	An Update on the Management of Acute High-Risk Pulmonary Embolism. Journal of Clinical Medicine, 2022, 11, 4807.	1.0	9
62	Unprovoked Submassive Saddle Pulmonary Embolism in an Adult Male After Pfizer COVID-19 Vaccination. Cureus, 2022, , .	0.2	0
63	A case of venous thromboembolism caused by protein C deficiency due to a novel gene mutation. Journal of Cardiology Cases, 2022, 26, 360-363.	0.2	3
64	Catheter-directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute pulmonary embolism. The Cochrane Library, 2022, 2022, .	1.5	8
65	The Incidence, Risk Factors, Characteristics and Prognosis of Recurrent Deep Venous Thrombosis in the Contralateral Lower Extremity. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, , .	0.9	0
66	Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta-analysis. Medicina Clínica, 2023, 160, 245-252.	0.3	2
67	Bioequivalence and Pharmacokinetic Study of 2 Edoxaban Tablets in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development, 2022, 11, 1440-1446.	0.8	1
68	Systematic search for the UBA1 mutation in men after a first episode of venous thromboembolism: A monocentric study. Journal of Thrombosis and Haemostasis, 2022, 20, 2697-2699.	1.9	8
69	Long-term clinical outcomes in older patients with acute venous thromboembolism who have renal impairment. Thrombosis Research, 2022, 218, 64-71.	0.8	1
70	Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team. Journal of Thrombosis and Thrombolysis, 2022, 54, 449-460.	1.0	7
71	Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review. Seminars in Thrombosis and Hemostasis, 0, , .	1.5	0
72	Subclavian Effort Thrombosis: Pathophysiology, Diagnosis, and Management. Seminars in Interventional Radiology, 2022, 39, 304-311.	0.3	1
73	Intermediate-Risk Pulmonary Embolism: A Review of Contemporary Diagnosis, Risk Stratification and Management. Medicina (Lithuania), 2022, 58, 1186.	0.8	6
75	Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures. Pharmacotherapy, 2022, 42, 780-791.	1.2	7
77	Anticoagulant use and associated outcomes in older patients receiving home palliative care: a retrospective cohort study. Cmaj, 2022, 194, E1198-E1208.	0.9	4
78	Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review. Seminars in Thrombosis and Hemostasis, 0, , .	1.5	2
79	Thrombolysis versus unfractionated heparin for hemodynamically stable patients with pulmonary embolism: a systematic review and meta-analysis. Russian Journal of Cardiology, 2022, 27, 5120.	0.4	1

#	ARTICLE	IF	CITATIONS
80	A Description of Apixaban Dosing Patterns for Treatment or Prevention of Thrombotic Events in Hospitalized Patients on Dialysis. <i>Hospital Pharmacy</i> , 0, , 001857872211153.	0.4	2
81	Concomitant Deep Vein Thrombosis in Cancer Patients with Unsuspected Pulmonary Embolism. <i>Cancers</i> , 2022, 14, 4510.	1.7	0
82	Should ultrasound evaluation for catheter-related thrombosis always be required before PICC removal?. <i>Journal of Vascular Access</i> , 0, , 112972982211259.	0.5	0
83	Dual Anticoagulation With Warfarin and Apixaban: A Case Report. <i>Cureus</i> , 2022, , .	0.2	0
84	Management of Massive Pulmonary Embolism. <i>International Journal of Angiology</i> , 2022, 31, 194-197.	0.2	0
85	Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti-Xa concentrations. <i>Pharmacotherapy</i> , 2022, 42, 768-779.	1.2	0
86	Dilemmas in the Choice of Adequate Therapeutic Treatment in Patients with Acute Pulmonary Embolism—From Modern Recommendations to Clinical Application. <i>Pharmaceuticals</i> , 2022, 15, 1146.	1.7	1
87	Muscular Calf Vein Thrombosis Is Associated With Increased 30-Day Mortality But Not 90-Day Mortality in Older Patients With Hip Fracture. <i>American Journal of Cardiology</i> , 2022, 184, 141-146.	0.7	3
89	Identification of outcomes in clinical studies of interventions for venous thromboembolism in non-pregnant adults. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2204-2206.	1.9	0
90	Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2022, 175, ITC129-ITC144.	2.0	31
91	Protecting patients during a shortage of thrombolytic agents. <i>Lancet, The</i> , 2022, 400, 1193-1194.	6.3	2
92	Comparative Effectiveness and Safety of Extended Anticoagulant Therapy among Medicare Beneficiaries with Venous Thromboembolism. <i>Clinical and Translational Science</i> , 0, , .	1.5	1
93	Complications of Vascular Disease. <i>Anesthesiology Clinics</i> , 2022, 40, 587-604.	0.6	0
94	Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1677-1695.	1.6	3
95	Synoptic reporting accuracy for computed tomography pulmonary arteriography among patients suspected of pulmonary embolism. <i>Journal of the American College of Emergency Physicians Open</i> , 2022, 3, .	0.4	1
96	Prescribing Trends of Oral Anticoagulants from 2010 to 2020 in Shanghai, China: A Retrospective Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211325.	0.7	4
97	Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project. <i>Life</i> , 2022, 12, 1657.	1.1	1
99	Utilization trends and outcomes of catheter-directed thrombolysis for pulmonary embolism in the US by race/ethnicity. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 675-685.	1.0	2

#	ARTICLE	IF	CITATIONS
100	What Is the Efficacy of Catheter-Directed Thrombolysis Versus Systemic Anticoagulation Alone for Submassive Pulmonary Embolism?. <i>Annals of Emergency Medicine</i> , 2022, , .	0.3	0
101	Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project. <i>Life</i> , 2022, 12, 1725.	1.1	1
102	Warfarin Is the Preferred Therapy for Patients With Thrombotic APS. <i>Journal of the American College of Cardiology</i> , 2023, 81, 31-33.	1.2	1
103	Standardization of Pulmonary Embolism Evaluation and Management Through Implementation of a Pulmonary Embolism Response Team: A Single-Center Experience at Brooke Army Medical Center. <i>Military Medicine</i> , 0, , .	0.4	0
104	Dilemmas Related to Direct-Acting Oral Anticoagulant Administration in Patients With Extreme Obesity. <i>Annals of Pharmacotherapy</i> , 0, , 106002802211304.	0.9	0
105	Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	1
106	Advancing anticoagulation stewardship: A call to action for stewardship from the US-based anticoagulation forum. <i>Thrombosis Update</i> , 2022, , 100125.	0.4	3
107	Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis. <i>Vascular Health and Risk Management</i> , 0, Volume 18, 793-807.	1.0	2
108	Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation. <i>Journal of Clinical Medicine</i> , 2022, 11, 5970.	1.0	1
109	Machine learning algorithm as a prognostic tool for venous thromboembolism in allogeneic transplant patients. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 57.e1-57.e10.	0.6	0
110	Multidisciplinary Care for the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer-Associated Thrombosis (CAT): Impact of Educational Interventions on CAT-Related Events and on Patientsâ€™ and Cliniciansâ€™ Awareness. <i>Life</i> , 2022, 12, 1594.	1.1	3
111	Length of Anticoagulation in Provoked Venous Thromboembolism: A Multicenter Study of How Realâ€World Practice Mirrors Guideline Recommendations. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	1
112	Contemporary Perioperative Management of Direct Oral Anticoagulants. <i>Advances in Anesthesia</i> , 2022, 40, 93-109.	0.5	0
113	Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19. <i>Annals of Pharmacotherapy</i> , 0, , 106002802211368.	0.9	0
115	Use of YEARS Algorithm in Military Health Care Beneficiaries to Evaluate Use of Computed Tomography Pulmonary Angiography. <i>Military Medicine</i> , 0, , .	0.4	0
116	Deep vein thrombosis symptoms and 30-day mortality in acute pulmonary embolism. <i>European Journal of Internal Medicine</i> , 2023, 108, 43-51.	1.0	1
117	Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism. <i>JACC: CardioOncology</i> , 2022, 4, 507-518.	1.7	6
118	Effectiveness and safety of rivaroxaban in patients with venous thromboembolism and active cancer: A subanalysis of the J'actly study. <i>Journal of Cardiology</i> , 2023, 81, 268-275.	0.8	0

#	ARTICLE	IF	CITATIONS
119	Comparison of bleeding following gastrointestinal endoscopic biopsy in patients treated with and without direct oral anticoagulants. <i>Endoscopy International Open</i> , 2023, 11, E52-E59.	0.9	2
120	A Review of the Past, Present and Future of Cancer-associated Thrombosis Management. <i>Heart International</i> , 2022, 16, 117.	0.4	2
122	COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE RISK OF THROMBOEMBOLIC EVENTS AND CURRENT OPTIONS FOR ANTITHROMBOTIC PROPHYLAXIS. , 2022, , 88-103.	0.3	0
123	Upper Extremity Deep Venous Thrombosis: Etiologies, Diagnosis, and Updates in Therapeutic Strategies. <i>Seminars in Interventional Radiology</i> , 2022, 39, 475-482.	0.3	0
124	Effectiveness and safety of the direct oral anticoagulant in acute distal deep vein thrombosis: From the prospective multicenter observational study, Jâ€™xactly, in Japan. <i>Phlebology</i> , 0, , 026835552211413.	0.6	0
125	Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad TromboembÃ³lica registry. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
126	Catheter-Directed Interventions for the Treatment of Lower Extremity Deep Vein Thrombosis. <i>Life</i> , 2022, 12, 1984.	1.1	5
127	Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	5
128	Mechanical thrombectomy versus catheter directed thrombolysis in patients with pulmonary embolism: A multicenter experience. <i>Catheterization and Cardiovascular Interventions</i> , 2023, 101, 140-146.	0.7	4
129	Risk factors of venous thromboembolism after incisional ventral hernia repair. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 0, , .	0.9	2
130	The incidence of deep vein thrombosis after anterior cruciate ligament reconstruction: An analysis using routine ultrasonography of 260 patients. <i>PLoS ONE</i> , 2022, 17, e0279136.	1.1	0
131	Chemotherapy Induced Cardiotoxicity: A State of the Art Review on General Mechanisms, Prevention, Treatment and Recent Advances in Novel Therapeutics. <i>Current Problems in Cardiology</i> , 2023, 48, 101591.	1.1	11
132	A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry. <i>Medicina (Lithuania)</i> , 2023, 59, 181.	0.8	0
133	Safety of discontinuation of anticoagulants after venous thromboembolism: whether D-dimer level should be taken into account?. <i>Atherothrombosis</i> , 2023, 12, 22-31.	0.1	0
134	Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study. <i>BMC Musculoskeletal Disorders</i> , 2023, 24, .	0.8	6
135	A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK. <i>Current Medical Research and Opinion</i> , 2023, 39, 483-495.	0.9	0
136	Venous thromboembolism associated with estrogenâ€™containing contraceptives versus any hormonal risk factor: aâ€™comparison of recurrence rates. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 175-178.	1.9	0
137	Endovascular Venous Interventions - A State-of-the-Art Review. <i>Current Problems in Cardiology</i> , 2023, 48, 101534.	1.1	3

#	ARTICLE	IF	CITATIONS
138	Unusual cause of retroperitoneal hemorrhage: Acute deep vein thrombosis. <i>Journal of Cardiology Cases</i> , 2023, 27, 165-167.	0.2	1
139	Interesting case of incidental diagnosis of pulmonary embolism by endobronchial ultrasonography. <i>BMJ Case Reports</i> , 2022, 15, e253943.	0.2	0
140	Systemic thrombolytic and ultrasound-assisted catheter-directed thrombolysis for treatment of acute pulmonary embolism: a 7-year, multicenter experience. <i>Journal of Thrombosis and Thrombolysis</i> , 0, , .	1.0	1
141	Thrombophilia and outcomes of venous thromboembolism in older patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100015.	1.0	0
142	Antithrombotic therapy in COVID-19 patients. <i>Obstetrics, Gynecology and Reproduction</i> , 2023, 16, 718-731.	0.2	1
143	Treatment and prevention of cancer-associated thrombosis in the Netherlands: A national survey. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100057.	1.0	2
144	Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, 107602962211295.	0.7	2
145	Inpatient pharmacyâ€driven antithrombosis stewardship efforts on warfarin to direct oral anticoagulant conversions. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2023, 6, 231-240.	0.5	0
146	Comparison of endovenous laser ablation and conservative treatment in acute thrombophlebitis of the varicose great saphenous vein: rationale, design and first results of clinical trial. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2023, 21, 3461.	0.4	2
147	Management and outcomes of calf deep vein thrombosis in patients with contraindication to full anticoagulation due to bleeding. <i>International Angiology</i> , 2023, 42, .	0.4	1
148	Acute phase characteristics and long-term complications of pulmonary embolism in COVID-19 compared to non-COVID-19 cohort: a large single-centre study. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	2
149	Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, , 100054.	1.0	0
150	Nitrous oxide misuse: a clue not to be missed in young patients with venous thromboembolism. <i>Clinical Medicine</i> , 2023, 23, 170-172.	0.8	1
151	Effectiveness and safety of catheter-directed thrombolysis in conjunction with percutaneous mechanical thrombectomy for acute iliofemoral deep vein thrombosis: A meta-analysis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2023, 11, 843-853.e2.	0.9	2
152	Reduced-Dose Thrombolysis in Acute Pulmonary Embolism A Systematic Review. <i>Angiology</i> , 2024, 75, 208-218.	0.8	3
153	Is it necessary to wear compression stockings and how long should they be worn for preventing post thrombotic syndrome? A meta-analysis of randomized controlled trials. <i>Thrombosis Research</i> , 2023, 225, 79-86.	0.8	2
154	High-risk pulmonary embolism in the intensive care unit. <i>Intensive Care Medicine</i> , 2023, 49, 579-582.	3.9	6
155	Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta-analysis. <i>Medicina Clnica (English)</i> Tj ETQq1 1o01784314rgBT /Ove		

#	ARTICLE	IF	CITATIONS
156	The oft-overlooked cardiovascular complications of inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2023, 19, 375-391.	1.3	5
157	<i>Antithrombotische Therapie.</i> , 2022, , 233-263.		0
158	Percutaneous Management of High-Risk Pulmonary Embolism. <i>Circulation: Cardiovascular Interventions</i> , 2023, 16, .	1.4	7
159	Lack of Funding for Direct-Acting Oral Anticoagulants for the Treatment of Pulmonary Embolism in Spain: Why and Until When. <i>Archivos De Bronconeumologia</i> , 2023, , .	0.4	0
160	Chemoprophylaxis and Management of Venous Thromboembolism in Microvascular Surgery. <i>Seminars in Plastic Surgery</i> , 2023, 37, 057-072.	0.8	1
161	DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 55, 685-690.	1.0	5
162	<scp>Warfarinâ€Rifampinâ€Gene</scp> (WARIFâ€G) Interaction: AÂRetrospective, Genetic, <scp>Caseâ€Control</scp> Study. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 1150-1159.	2.3	1
163	Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism: Results of an Expert Consensus Panel. <i>American Journal of Medicine</i> , 2023, 136, 523-533.	0.6	6
164	Saddle Pulmonary Embolism and Atrial Fibrillation. <i>Clinical Cases in Cardiology</i> , 2023, , 29-34.	0.0	0
166	Barriers and facilitators to interhospital transfer of acute pulmonary embolism: An inductive qualitative analysis. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	2
167	In Situ Pulmonary Arterial Thrombosis: Literature Review and Clinical Significance of a Distinct Entity. <i>American Journal of Roentgenology</i> , 2023, 221, 57-68.	1.0	6
168	Updated Trends in Inferior Vena Cava Filter Use by Indication in the United States After Food and Drug Administration Safety Warnings: A Decade Analysis From 2010 to 2019. <i>Journal of Endovascular Therapy</i> , 0, , 152660282311560.	0.8	1
169	Coagulopathy and Emergent Reversal of Anticoagulation. <i>Anesthesiology Clinics</i> , 2023, 41, 249-261.	0.6	0
170	Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism. <i>Clinical and Translational Science</i> , 2023, 16, 946-954.	1.5	0
171	Clinical course and treatment of incidentally detected splanchnic vein thrombosis: an individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1592-1600.	1.9	5
172	Fake-news-free evidence-based communication for proper vein-lymphatic disease management. <i>International Angiology</i> , 2023, 42, .	0.4	1
173	Anatomic distribution of lower extremity deep venous thrombosis is associated with an increased risk of pulmonary embolism: A 10-year retrospective analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	3
174	Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020. <i>JAMA Network Open</i> , 2023, 6, e234059.	2.8	8

#	ARTICLE	IF	CITATIONS
176	Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study. <i>Lancet Haematology</i> , 2023, 10, e359-e366.	2.2	4
177	Common congenital heart problems in acute and intensive care. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2023, 12, 267-279.	0.4	0
178	Low D-dimer levels at diagnosis of venous thromboembolism are associated with reduced risk of recurrence: data from the TROLL registry. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1861-1868.	1.9	1
179	Risk Factors, Clinical Presentation, Therapeutic Trends, and Outcomes in Arterial Thrombosis Complicating Unvaccinated COVID-19 Patients: A Systematic Review. <i>Angiology</i> , 0, , 000331972311670.	0.8	1
180	Editor's Choice "European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. <i>European Journal of Vascular and Endovascular Surgery</i> , 2023, 65, 627-689.	0.8	29
181	Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2151-2162.	1.9	5
182	Initiative to reduce inappropriate venous thromboembolism prophylaxis in an 11-hospital safety net system: An electronic health records-based approach. <i>Journal of Hospital Medicine</i> , 0, , .	0.7	0
183	Comparative outcomes of anticoagulation alone versus anticoagulation plus endovascular intervention in adults with isolated renal vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2023, 11, 816-823.	0.9	5
184	THROMBOLYSIS IN PULMONARY EMBOLISM TREATMENT. <i>Wiadomości Lekarskie</i> , 2023, 76, 604-609.	0.1	0
185	Prolonged Fasting as a Cause of Deep Vein Thrombosis: A Case Report. <i>TH Open</i> , 2023, 07, e94-e96.	0.7	1
186	Mental Health and Quality of Life in Pulmonary Embolism: A Literature Review. <i>Advances in Respiratory Medicine</i> , 2023, 91, 174-184.	0.5	2
187	The hazard of therapeutic doses of anticoagulants in patients with isolated subsegmental pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 0, , .	1.0	0
213	Special Populations: Pulmonary Embolism and Heparin-Induced Thrombocytopenia and Thrombosis. , 2023, , 1-13.		0
217	Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease. <i>American Journal of Cardiovascular Drugs</i> , 2023, 23, 247-255.	1.0	0
255	Antiphospholipid Syndrome: State of the Art of Clinical Management. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	1
265	Thromboembolic prophylaxis in neurosurgical practice: a systematic review. <i>Acta Neurochirurgica</i> , 0, , .	0.9	0
271	Special Populations: Pulmonary Embolism and Heparin-Induced Thrombocytopenia and Thrombosis. , 2023, , 1-13.		0
272	Long-Term Medical Management. , 2023, , 307-313.		0

#	ARTICLE	IF	CITATIONS
290	Case report: hunting the hidden: surgical treatment of chronic silent thrombus in the left ventricle in a young alcoholic patient with myocardial bridging. Journal of Cardiothoracic Surgery, 2023, 18, .	0.4	0
296	Verl�ngerte medikament�se Sekund�rprophylaxe ven�ser Thromboembolien (VTEs). Springer Reference Medizin, 2023, , 1-5.	0.0	0
300	Risikofaktoren f�r Rezidive ven�ser Thromboembolien (VTE). Springer Reference Medizin, 2023, , 1-11.	0.0	0
303	Describing Lower Limb Deep Vein Thrombosis: Needs More Than Just the Knee. , 2023, , 339-341.		0
323	DOACs for the Medical Management of Venous Thromboembolism in Adults. , 0, , .		0
326	SAMe-TT2R2 Score to Predict Time in Therapeutic Range of Vitamin K Antagonists in Asian and Non-Asian patients: A Systematic Review and Meta-analysis. American Journal of Cardiovascular Drugs, 2024, 24, 211-240.	1.0	0
332	Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension. , 0, , .		0
342	Antithrombotische Therapie. , 2023, , 255-287.		0